BioPharm Asia, Inc. Announces Approval of 15c2-11 Filing and Anticipates OTCBB Listing
Published: Dec 18, 2012
TONGHUA, CHINA--(Marketwire - December 18, 2012) - Biopharm Asia, Inc. (PINKSHEETS: BFAR) is pleased to announce that Biopharm Asia, Inc. received approval for the recently submitted 15c2-11 filing late on Friday Dec 14th.
The Company will now seek listing with the OTC Bulletin Board at the earliest possible opportunity.
This is a significant step in the growth and development of Biopharm Asia, Inc. The approval and the subsequent OTC listing will allow the company to access additional capital market and investors through new merger and acquisition targets. Biopharm Asia is excited to continue its commitment to increasing transparency, exposure and providing liquidity for its shareholders.
The information in this release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements, specifically statements relating to listing and trading on the OTCBB, contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Biopharm Asia to be materially different from the statements made herein. Although the Company believes that its expectations are based on reasonable assumptions, actual results may differ materially.
Biopharm Asia, Inc